One Year Extension Study To Protocol C2/5/TZ:MS-05
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Open label, one year extension study to evaluate the clinical efficacy and safety of 12 mg
sublingual tizanidine administered once nightly in MS patients who successfully completed
Phase I/II protocol C2/5/TZ:MS-05 at the Tel Aviv Sourasky Medical Center, Department of
Neurology, Dr. Arnon Karni, PI.